Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

American Journal of Hematology

Volumn 89, Issue 11, 2014, Pages E206-E211

  García Gutiérrez, Valentin ^a   Puerta, Jose Manuel ^b   Maestro, Begoña ^c   Casado Montero, Luis Felipe ^d   Muriel, Alfonso ^a   Molina Hurtado, Jose Ramon ^e   Perez Encinas, Manuel ^f   Moreno Romero, Maria Victoria ^g   Suñol, Pere Barba ^h   Sola Garcia, Ricardo ⁱ   De Paz, Raquel ^j   Ramirez Sanchez, Maria Jose ^k   Osorio, Santiago ^l   Mata Vazquez, Maria Isabel ^m   Martinez López, Joaquin ⁿ   Sastre, Jose Luis ^o   Portero, Maria de los Angles ^p   Bautista, Guiomar ^q   Duran Nieto, Maria Soledad ^r   Giraldo, Pilar ^s   Jimenez Jambrina, Margarita ^t   Burgaleta, Carmen ^u   Ruiz Aredondo, Joaquin ^v   Peñarrubia, Maria Jesús ^w   Requena, Maria José ^x   Fernández Valle, María del Carmen ^y   Calle, Carmen ^z   Paz Coll, Antonio ^aa   Hernández Rivas, Jose Ángel ^ab   Franco Osorio, Rafael ^ac   Cano, Pilar ^ad   Tallón Pérez, David ^ae   Fernández de la Mata, Margarita ^af   Garrido, Pilar López ^b   Steegmann, Juan Luis ^c,ag,ah,ai   more..

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^c Registro Español De Investigación Y Tratamiento De Leucemia Mieloide Cronica RELMC   (Spain)

^d HOSPITAL VIRGEN DE LA SALUD   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^g HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^h HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁱ HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^j HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^k HOSPITAL DE JEREZ   (Spain)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m HOSPITAL COSTA DEL SOL   (Spain)

ⁿ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^o Nephrology Department   (Spain)

^p HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^q HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^r Hosp Univ Ciudad de Jaén   (Spain)

^s HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^t Hospital Comarcal de Riotinto   (Spain)

^u HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^v HOSPITAL DE ANTEQUERA   (Spain)

^w HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^x HOSPITAL SEVERO OCHOA   (Spain)

^y HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^z HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^aa HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^ab HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^ac HOSPITAL PUNTA DE EUROPA   (Spain)

^ad HOSPITAL GENERAL LA MANCHA CENTRO   (Spain)

^ae HOSPITAL SAN AGUSTÍN   (Spain)

^af HOSPITAL INFANTA MARGARITA   (Spain)

^ag HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^ah Grupo Español de Leucemia Mieloide Crónica GELMC   (Spain)

^ai Registro Andaluz de Leucemia Mieloide Crónica RALMC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLEURA EFFUSION; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TIME TO TREATMENT; TREATMENT RESPONSE; WATCHFUL WAITING;

EID: 85027935126     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23816     Document Type: Article

References (20)

1. Björkholm M, Ohm L, Eloranta S, et al. The success story of targeted therapy in chronic myeloid leukemia: A population based study of 3173 patients diagnosed in Sweden 1973–2008. J Clin Oncol 2011;28:2514–2525.
2. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809–1820.
3. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
4. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013;122:872–884.
5. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008;112:4437–4444.
6. Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer 2009;115:3709–3718.
7. Castagnetti F, Gugliotta G, Palandri F, et al. Chronic myeloid leukemia (CML) patients with “suboptimal” response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to “optimal” responders: A GIMEMA CML Working Party analysis. Blood 2009;114 (ASH abstract no. 2196).
8. Breccia M, Orlandi SM, Latagliata R, et al. Suboptimal response to imatinib according to 2006–2009 European LeukemiaNet criteria: A 'grey zone' at 3, 6 and 12 months identifies chronic myeloid leukemia patients who need early intervention. Br J Haematol 2011;152:119–121.
9. Druker BJ, Guilhot F, O'Brien SG, et al. Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2009;355:2408–2417.
10. Ailawadhi S, Miller CB, Jilella AP, et al. Effect of nilotinib on molecular response in chronic myelogenous leukemia-chronic phase (CML-CP) patients with suboptimal molecular response to imatinib-ENABL study update. Blood 2011;118 (ASH abstract no. 2771).
11. Goh HG, Jootar S, Kim HJ, et al. Efficacy of nilotinib versus high dose imatinib in early chronic phase CML patients who have suboptimal molecular responses to standard-dose imatinib (RE-NICE multi center study). Blood 2011;118 (ASH abstract no. 2765).
12. Hughes TP, Lipton H, Spector N, et al. Switching to nilotinib is associated with continued deeper molecular responses in CML-CP patients with minimal residual disease after ≥ 2 years on imatinib: Enestcmr 2-Year Follow-up results. Blood 2012;120 (ASH abstract no. 694).
13. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28–37.
14. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010;116:3758–3765.
15. Marin D, Ibrahim AR, Lucas CM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol 2012;30:232–238.
16. Hanfstein B, Müller MC, Hehlmann R, et al. Early molecular and cytogenetic response is predictive of long-term progression-free and overall survival in chronic myeloid leukemia. Leukemia 2012;26:2096–2102.
17. Marin D, Hedgley C, Clark RE, et al. Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib. Blood 2012;120:291–294.
18. Hehlmann R, Müller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV. J Clin Oncol 2014;32:415–423.
19. Falchi L, Kantarjian HM, Wang X, et al. Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosin kinase inhibitors. Am J Hematol 2013;88:1024–1029.
20. Etienne G, Dulucq S, Nicolini FE, et al. Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib frontline therapy. Haematologica 2014;99:458–464.